search
Back to results

Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve (RESERVE)

Primary Purpose

Hypertension, Cardiovascular Risk Factors

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Rosuvastatin
Sponsored by
Asan Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Rosuvastatin, Coronary flow reserve

Eligibility Criteria

35 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Controlled Hypertension: treated SBP < 140 mmHg and DBP < 90 mmHg
  • LDL cholesterol > 130 mg/dL
  • Patients with statin-naive state, defined as receiving no statin therapy for more than 3 months during the previous 12 months
  • Any 1 of these cardiovascular risk factors required: smoking, Type 2 DM, age over 55 (men) or 65 (women), peripheral vascular disease, history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol < 40 mg/dL

Exclusion Criteria:

  • A previous history of intolerance or hypersensitivity to statins
  • Uncontrolled hypertension; SBP ≥ 140 mmHg or DBP ≥ 90 mmHg
  • Previous MI or currently treated angina pectoris
  • Stroke, Transient ischemic attack < 3 months
  • Secondary hypertension
  • Fasting serum triglyceride > 500 mg/dL
  • Clinical congestive heart failure
  • Uncontrolled arrhythmia
  • Left ventricular hypertrophy: LV mass index > 134g/m2 (male) or >110g/m2 (female)
  • Concomitant clinically important respiratory, hematological, gastrointestinal, hepatic, renal or other disease
  • Pregnant or lactating women and those of child-bearing potential

Sites / Locations

  • Asan Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Rosuvastatin

Arm Description

Rosuvastatin 10mg qd for 12 months.

Outcomes

Primary Outcome Measures

Change of coronary flow velocity reserve
Change of coronary flow velocity reserve from baseline to 1 year follow-up. For each patient, the averaged value of coronary flow velocity reserve will be obtained at baseline and 1 year follow-up.

Secondary Outcome Measures

Change of averaged peak diastolic velocity
Change of averaged peak diastolic velocity from baseline to study end.
Change of CRP
Change of CRP from baseline to study end.
Change of LDL cholesterol
Change of LDL cholesterol from baseline to study end.

Full Information

First Posted
December 9, 2011
Last Updated
May 8, 2014
Sponsor
Asan Medical Center
Collaborators
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT01490398
Brief Title
Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve
Acronym
RESERVE
Official Title
Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
Collaborators
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In ASCOT study, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol. However, the underlying mechanism of statins to improve clinical outcomes in hypertension is unclear and the effect of statins on coronary flow reserve (CFR) has not been examined in hypertensive patients. Therefore, it is clinically important and timely project to measure CFR non-invasively using echocardiography and to elucidate the mechanism of clinical benefits of statins in hypertensive patients with cardiovascular risk. The investigators try to evaluate the effect of rosuvastatin on CFR by measuring the change of CFR after 1 year treatment of rosuvastatin, and to correlate CFR with LDL-cholesterol and CRP.
Detailed Description
In hypertensive patients with high risk, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol. However, the underlying mechanism of statins to improve clinical outcomes in hypertension is unclear. In patients with hypercholesterolemia or coronary atherosclerosis, several studies reported that level of LDL-cholesterol was inversely correlated with coronary blood flow reserve and suggested that statin improved coronary blood flow. Although it is speculated that statin may improve coronary blood flow by decreasing LDL cholesterol level and stabilizing atherosclerotic plaque in coronary atherosclerosis, the effect of statins on coronary flow reserve (CFR) has not been examined in hypertensive patients. LDL cholesterol is expected to significantly decrease when rosuvastatin 20mg is administered. In addition to LDL-cholesterol lowering effect, the stabilization of atherosclerotic plaque and the regression of atheroma are observed during rosuvastatin treatment. Because of these beneficial effects of rosuvastatin, it may be expected that rosuvastatin will improve coronary blood flow even in hypertensive patients without hypercholesterolemia and the efficacy of rosuvastatin on CFR needs to be investigated in hypertensive patients with cardiovascular risk. Morphologic assessment for the measurement of coronary lumen in the invasive coronary angiography is used as a gold standard to assess the stenosis in coronary diseases. However, as decrease of myocardial blood flow due to coronary artery disease could not be exactly evaluated by morphologic stenosis, the functional test was required to assess the significance of coronary artery stenosis, and CFR could be directly measured using Doppler guide wire since mid-1990s. Since the pathophysiological implication of coronary stenosis can be assessed using CFR measurement, CFR value is widely used in clinical practice as a very useful indicator to assess coronary stenosis severity in performing percutaneous coronary intervention. As a high frequency transducer with excellent resolution has been used, coronary artery can be directly imaged, and coronary flow velocity can be measured using echo-Doppler technique. As a result, CFR is easily measured in an echocardiography lab which could be measured only in a cardiac catheterization lab using Doppler guide wire in the past. It was confirmed that CFR values obtained by Doppler technique were same as those invasively obtained in a cardiac catheterization lab. The clinical usefulness and accuracy of the technique have been verified also in the diagnosis of coronary artery disease. Therefore, it is clinically important and timely project to measure CFR non-invasively using echocardiography and to elucidate the mechanism of clinical benefits of statins in hypertensive patients with cardiovascular risk. We try to evaluate the effect of rosuvastatin on CFR by measuring the change of CFR after 1 year treatment of rosuvastatin, and to correlate CFR with LDL-cholesterol and CRP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Cardiovascular Risk Factors
Keywords
Hypertension, Rosuvastatin, Coronary flow reserve

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
56 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rosuvastatin
Arm Type
Experimental
Arm Description
Rosuvastatin 10mg qd for 12 months.
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Crestor
Intervention Description
After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
Primary Outcome Measure Information:
Title
Change of coronary flow velocity reserve
Description
Change of coronary flow velocity reserve from baseline to 1 year follow-up. For each patient, the averaged value of coronary flow velocity reserve will be obtained at baseline and 1 year follow-up.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change of averaged peak diastolic velocity
Description
Change of averaged peak diastolic velocity from baseline to study end.
Time Frame
12 months
Title
Change of CRP
Description
Change of CRP from baseline to study end.
Time Frame
12 months
Title
Change of LDL cholesterol
Description
Change of LDL cholesterol from baseline to study end.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Controlled Hypertension: treated SBP < 140 mmHg and DBP < 90 mmHg LDL cholesterol > 130 mg/dL Patients with statin-naive state, defined as receiving no statin therapy for more than 3 months during the previous 12 months Any 1 of these cardiovascular risk factors required: smoking, Type 2 DM, age over 55 (men) or 65 (women), peripheral vascular disease, history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol < 40 mg/dL Exclusion Criteria: A previous history of intolerance or hypersensitivity to statins Uncontrolled hypertension; SBP ≥ 140 mmHg or DBP ≥ 90 mmHg Previous MI or currently treated angina pectoris Stroke, Transient ischemic attack < 3 months Secondary hypertension Fasting serum triglyceride > 500 mg/dL Clinical congestive heart failure Uncontrolled arrhythmia Left ventricular hypertrophy: LV mass index > 134g/m2 (male) or >110g/m2 (female) Concomitant clinically important respiratory, hematological, gastrointestinal, hepatic, renal or other disease Pregnant or lactating women and those of child-bearing potential
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Duk Hyun Kang, MD, PhD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
25159238
Citation
Sun BJ, Hwang E, Jang JY, Kim DH, Song JM, Kang DH. Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension. Am J Cardiol. 2014 Oct 15;114(8):1234-7. doi: 10.1016/j.amjcard.2014.07.046. Epub 2014 Jul 30.
Results Reference
derived

Learn more about this trial

Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve

We'll reach out to this number within 24 hrs